Suppr超能文献

人类胆管癌发生过程中涉及的多种基因改变:一项分子遗传学与临床病理研究

Multiple genetic alterations involved in the tumorigenesis of human cholangiocarcinoma: a molecular genetic and clinicopathological study.

作者信息

Cong W M, Bakker A, Swalsky P A, Raja S, Woods J, Thomas S, Demetris A J, Finkelstein S D

机构信息

Department of Pathology, Oriental Hepatobiliary Surgery Hospital, Shanghai, 200438, PR China.

出版信息

J Cancer Res Clin Oncol. 2001;127(3):187-92. doi: 10.1007/s004320000194.

Abstract

PURPOSE

Cholangiocarcinoma (CC) is the second most common malignant tumor in the liver and the molecular genetic alterations involved in the tumorigenesis of CC have not been well studied.

PATIENTS AND METHODS

The authors analyzed the loss of heterozygosity (LOH) in four tumor suppressor genes, including the adenomatous polyposis coli (APC) gene, the deleted in colon cancer (DCC) gene, the 8-hydroguanine-specific DNA glycosylase (OGG1) gene, and the p53 gene in 22 surgically resected primary CCs by using microdissection-based PCR amplification and direct DNA sequencing.

RESULTS

A total of 19 (86.4%) out of 22 CCs exhibited genetic alterations, of which 11 (57.9%) and eight (42.1%) cases showed one and more than one gene alterations, respectively. The frequency of genetic alterations of the four genes studied ranged in order from high to low as APC (68.8%) > DCC (46.2%) > OGG1 (41.7%) > p53 (37.5%). Based on the pattern of altered genes and their correlation with clinical and pathological parameters, the genetic alterations were classified into three groups: group I: no detectable genetic alterations (n = 3, 13.6%); group II: LOH in APC and/or DCC (n = 9, 40.9%); and group III: LOH in OGG1 and/or p53 occurred separately or combined with LOH in APC and/or DCC (n = 10, 45.5%). The > or = 3-year survival rates between group II and group III are 88.9% and 30%, respectively (P < 0.05). No significant differences were found between genetic alterations and tumor size, tumor type, tumor invasion, TNM staging, and tumor differentiation (P > 0.05).

CONCLUSION

Accumulation of multiple genetic alterations are involved in the tumorigenesis of CC, of which genetic alterations of APC and DCC occur at a relatively early stage, and of OGG1 and p53 occur at a relatively late stage during development of CC.

摘要

目的

胆管癌(CC)是肝脏中第二常见的恶性肿瘤,而参与CC肿瘤发生的分子遗传学改变尚未得到充分研究。

患者与方法

作者通过基于显微切割的聚合酶链反应(PCR)扩增和直接DNA测序,分析了22例手术切除的原发性CC中四个肿瘤抑制基因的杂合性缺失(LOH)情况,这四个基因包括腺瘤性息肉病 coli(APC)基因、结肠癌缺失(DCC)基因、8-羟基鸟嘌呤特异性DNA糖基化酶(OGG1)基因和p53基因。

结果

22例CC中共有19例(86.4%)表现出基因改变,其中11例(57.9%)和8例(42.1%)分别显示一个和一个以上的基因改变。所研究的四个基因的基因改变频率从高到低依次为APC(68.8%)>DCC(46.2%)>OGG1(41.7%)>p53(37.5%)。根据改变基因的模式及其与临床和病理参数的相关性,基因改变分为三组:第一组:未检测到基因改变(n = 3,13.6%);第二组:APC和/或DCC中的LOH(n = 9,40.9%);第三组:OGG1和/或p53中的LOH单独出现或与APC和/或DCC中的LOH合并出现(n = 10,45.5%)。第二组和第三组的3年及以上生存率分别为88.9%和30%(P < 0.05)。基因改变与肿瘤大小、肿瘤类型、肿瘤侵袭、TNM分期和肿瘤分化之间未发现显著差异(P > 0.05)。

结论

多种基因改变的积累参与了CC的肿瘤发生,其中APC和DCC的基因改变发生在相对早期,而OGG1和p53的基因改变发生在CC发展的相对晚期。

相似文献

4
Loss of WWOX expression in human extrahepatic cholangiocarcinoma.WWOX表达在人肝外胆管癌中的缺失。
J Cancer Res Clin Oncol. 2009 Jan;135(1):39-44. doi: 10.1007/s00432-008-0449-4. Epub 2008 Jul 16.
5
Gene therapy for people with hepatocellular carcinoma.肝细胞癌的基因治疗。
Cochrane Database Syst Rev. 2024 Jun 4;6(6):CD013731. doi: 10.1002/14651858.CD013731.pub2.
8
Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma.可切除胆管癌的术后辅助化疗。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD012814. doi: 10.1002/14651858.CD012814.pub2.

引用本文的文献

6
The significance of genetics for cholangiocarcinoma development.遗传学在胆管癌发生发展中的意义。
Ann Transl Med. 2013 Oct;1(3):28. doi: 10.3978/j.issn.2305-5839.2012.10.04.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验